

AMENDMENTS TO THE CLAIMS

The following is a complete, marked-up listing of revised claims with a status identifier in parenthesis, underlined text indicating insertions, and strike through and/or double-bracketed text indicating deletions.

LISTING OF CLAIMS

1. (Currently Amended) A drug, comprising a substance to be transferred into a cell for treatment of a disease encapsulated in a hollow nanoparticle containing a particle-forming protein, the nanoparticle displaying a molecule, ~~such as a growth factor,~~ which binds with a particular molecule on a cell surface, wherein:

the molecule which binds with the particular molecule on a cell surface is selected from the group consisting of epidermal growth factors, interleukin, interferon, colony stimulating factors, tumor necrosis factors, transforming growth factor β , platelet-derived growth factors, erythropoietin, Fas antigens activin, bone morphogenetic factors, and nerve growth factors;

the protein is a modified hepatitis B virus surface antigen protein; and

the substance to be transferred into a cell is thymidine kinase (HSV1 tk) gene of herpes simplex virus type 1.

2. (Cancelled).

3. (Original) The drug as set forth in claim 1, wherein the substance to be transferred into a cell is a gene.

4. (Original) The drug as set forth in claim 3, wherein the gene is a cancer-treating gene.

5. (Cancelled).

6. (Original) The drug as set forth in claim 1, wherein said drug is administered to a human body through intravenous injection.

7. (Cancelled)

8. (Currently Amended) The drug as set forth in claim 21, wherein the substance to be transferred into a cell is a gene.

9. (Currently Amended) The drug as set forth in claim 21, wherein said drug is administered to a human body through intravenous injection.

10. (Original) The drug as set forth in claim 3, wherein said drug is administered to a human body through intravenous injection.

11. (Original) The drug as set forth in claim 4, wherein said drug is administered to a human body through intravenous injection.

12. (Currently Amended) The drug as set forth in claim 51, wherein said drug is administered to a human body through intravenous injection.

13-22. (Cancelled)

23. (New) The drug as set forth in claim 1, wherein the particular molecule on a cell surface is an epidermal growth factor receptor; and

the molecule which binds with the particular molecule on a cell surface is the epidermal growth factor.

24. (New) The drug as set forth in claim 23, wherein the drug is used to treat cancer which expresses the epidermal growth factor receptor.

25. (New) The drug as set forth in claim 24, wherein the cancer is human squamous cell carcinoma.